MX2021000029A - Profarmacos y moduladores de receptores nmda, sales y usos de estos. - Google Patents

Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Info

Publication number
MX2021000029A
MX2021000029A MX2021000029A MX2021000029A MX2021000029A MX 2021000029 A MX2021000029 A MX 2021000029A MX 2021000029 A MX2021000029 A MX 2021000029A MX 2021000029 A MX2021000029 A MX 2021000029A MX 2021000029 A MX2021000029 A MX 2021000029A
Authority
MX
Mexico
Prior art keywords
compounds
prodrugs
salts
nmda receptor
receptor modulators
Prior art date
Application number
MX2021000029A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MX2021000029A publication Critical patent/MX2021000029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se describen los compuestos que tienen potencia mejorada en la modulación de la actividad del receptor NMDA. Se contemplan dichos compuestos para su uso en el tratamiento de enfermedades y trastornos, tales como trastornos de aprendizaje, actividades cognitivas y analgesia, particularmente en el alivio y/o reducción de dolor neuropático. También se describen las formulaciones disponibles oralmente y otras formas de administración farmacéuticamente aceptables de los compuestos, que incluyen formulaciones intravenosas.
MX2021000029A 2013-10-28 2016-04-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos. MX2021000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28

Publications (1)

Publication Number Publication Date
MX2021000029A true MX2021000029A (es) 2021-03-25

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005510A MX2016005510A (es) 2013-10-28 2014-10-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.
MX2021000029A MX2021000029A (es) 2013-10-28 2016-04-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005510A MX2016005510A (es) 2013-10-28 2014-10-27 Profarmacos y moduladores de receptores nmda, sales y usos de estos.

Country Status (15)

Country Link
US (2) US9745342B2 (es)
EP (2) EP3062810A4 (es)
JP (1) JP6603668B2 (es)
KR (1) KR20160077153A (es)
CN (2) CN105764522A (es)
AU (2) AU2014342624A1 (es)
BR (1) BR112016009443A8 (es)
CA (1) CA2928701A1 (es)
CL (2) CL2016001001A1 (es)
IL (1) IL245302B (es)
MX (2) MX2016005510A (es)
RU (1) RU2016119830A (es)
SA (1) SA516371037B1 (es)
SG (2) SG10201810496XA (es)
WO (1) WO2015065891A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228313B1 (en) 2013-01-22 2019-09-11 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
CN116082461B (zh) * 2022-10-14 2023-11-14 浙江大学 一种具有抗菌活性的小分子肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030840A1 (ja) * 2004-09-14 2006-03-23 National Institute Of Advanced Industrial Scienceand Technology ムチン型ペプチドの合成法とｍｕｃ１関連糖ペプチド
US7960506B2 (en) * 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) * 2007-02-23 2019-04-16 爱勒让治疗公司 ***大环***
CN102186883B (zh) * 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
EP2342221B1 (en) * 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
CN102933226A (zh) * 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20140043078A (ko) * 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Also Published As

Publication number Publication date
CN105764522A (zh) 2016-07-13
CL2020002247A1 (es) 2021-02-05
SG11201603376UA (en) 2016-05-30
MX2016005510A (es) 2017-01-06
SG10201810496XA (en) 2018-12-28
CN112321678A (zh) 2021-02-05
IL245302A0 (en) 2016-06-30
CA2928701A1 (en) 2015-05-07
IL245302B (en) 2020-05-31
US9745342B2 (en) 2017-08-29
KR20160077153A (ko) 2016-07-01
RU2016119830A3 (es) 2018-07-02
CL2016001001A1 (es) 2016-12-16
EP3062810A1 (en) 2016-09-07
SA516371037B1 (ar) 2018-05-16
BR112016009443A8 (pt) 2020-03-24
AU2020201109A1 (en) 2020-03-05
US10590167B2 (en) 2020-03-17
JP2016537413A (ja) 2016-12-01
EP3564256A1 (en) 2019-11-06
RU2016119830A (ru) 2017-12-04
US20180127466A1 (en) 2018-05-10
WO2015065891A1 (en) 2015-05-07
US20160244485A1 (en) 2016-08-25
AU2014342624A1 (en) 2016-06-02
JP6603668B2 (ja) 2019-11-06
EP3062810A4 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
PH12015501601A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP2542254A4 (en) NMDA-RECEIVER MODULATORS WITH STABILIZED SECONDARY STRUCTURE AND USES THEREOF
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2014DN09434A (es)
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021000029A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.